Dyadic International, Inc. announced its financial results for the first quarter of 2025, reporting revenue of US$393.6 thousand. This represents an 18% increase compared to the first quarter of 2024, demonstrating continued growth.
The company also reported a net loss per share of US$0.068, an improvement from a US$0.07 loss per share in the prior year's first quarter. Dyadic expanded its life science and industrial portfolio with six additional life science products currently in development, advancing towards commercialization of functional recombinant solutions.
Significant progress includes an awarded research grant of up to $4.5 million from the Coalition for Epidemic Preparedness (CEPI) and launched research for a $3.0 million Gates Foundation grant for malaria and RSV antibody programs. Dyadic was also selected to participate in the inaugural meeting of the 'European Vaccines Hub for Pandemic Readiness,' highlighting its growing international recognition.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.